Does the media prefer BBIO or ACAD?

In the previous week, BridgeBio Pharma had 9 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat BridgeBio Pharma's score of 0.75 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACAD or ASND?

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 4 mentions for ACADIA Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat ACADIA Pharmaceuticals' score of 1.13 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or ACAD?

In the previous week, Axsome Therapeutics had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 17 mentions for Axsome Therapeutics and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Axsome Therapeutics' score of 0.23 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACAD or ELAN?

In the previous week, Elanco Animal Health had 12 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 16 mentions for Elanco Animal Health and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Elanco Animal Health's score of 0.90 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMMT or ACAD?

In the previous week, Summit Therapeutics had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Summit Therapeutics' score of 0.37 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ACADIA Pharmaceuticals (ACAD) Competitors

$21.84 +0.14 (+0.65%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$21.76 -0.08 (-0.37%)

As of 06/9/2026 06:28 PM Eastern

Compare

ACAD vs. BBIO, ASND, AXSM, ELAN, and SMMT

Should you buy ACADIA Pharmaceuticals stock or one of its competitors? MarketBeat compares ACADIA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ACADIA Pharmaceuticals include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 9 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat BridgeBio Pharma's score of 0.75 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 34.30% compared to BridgeBio Pharma's net margin of -124.42%. ACADIA Pharmaceuticals' return on equity of 9.61% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.40	-$724.93M	-$3.74	N/A
ACADIA Pharmaceuticals	$1.07B	3.49	$391M	$2.20	9.93

BridgeBio Pharma currently has a consensus price target of $89.59, indicating a potential upside of 32.37%. ACADIA Pharmaceuticals has a consensus price target of $31.63, indicating a potential upside of 44.80%. Given ACADIA Pharmaceuticals' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

ACADIA Pharmaceuticals beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 4 mentions for ACADIA Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat ACADIA Pharmaceuticals' score of 1.13 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals presently has a consensus target price of $31.63, suggesting a potential upside of 44.80%. Ascendis Pharma A/S has a consensus target price of $295.39, suggesting a potential upside of 38.53%. Given ACADIA Pharmaceuticals' higher possible upside, research analysts clearly believe ACADIA Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.49	$391M	$2.20	9.93
Ascendis Pharma A/S	$814.57M	16.33	-$258M	$8.67	24.59

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 57.87% compared to ACADIA Pharmaceuticals' net margin of 34.30%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

ACADIA Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats ACADIA Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 17 mentions for Axsome Therapeutics and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Axsome Therapeutics' score of 0.23 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics currently has a consensus price target of $251.26, suggesting a potential upside of 2.29%. ACADIA Pharmaceuticals has a consensus price target of $31.63, suggesting a potential upside of 44.80%. Given ACADIA Pharmaceuticals' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

ACADIA Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A
ACADIA Pharmaceuticals	$1.07B	3.49	$391M	$2.20	9.93

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Axsome Therapeutics' net margin of -26.59%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Summary

ACADIA Pharmaceuticals beats Axsome Therapeutics on 12 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Elanco Animal Health?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

ACADIA Pharmaceuticals currently has a consensus price target of $31.63, suggesting a potential upside of 44.80%. Elanco Animal Health has a consensus price target of $28.20, suggesting a potential upside of 15.18%. Given ACADIA Pharmaceuticals' higher possible upside, equities analysts clearly believe ACADIA Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Elanco Animal Health's net margin of -4.95%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%
Elanco Animal Health	-4.95%	7.42%	3.66%

ACADIA Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

In the previous week, Elanco Animal Health had 12 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 16 mentions for Elanco Animal Health and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Elanco Animal Health's score of 0.90 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	3.49	$391M	$2.20	9.93
Elanco Animal Health	$4.72B	2.59	-$232M	-$0.50	N/A

Summary

ACADIA Pharmaceuticals beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks.

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Summit Therapeutics had 13 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Summit Therapeutics' score of 0.37 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
ACADIA Pharmaceuticals	$1.07B	3.49	$391M	$2.20	9.93

Summit Therapeutics currently has a consensus price target of $26.05, suggesting a potential upside of 82.32%. ACADIA Pharmaceuticals has a consensus price target of $31.63, suggesting a potential upside of 44.80%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Summit Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Summary

ACADIA Pharmaceuticals beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACAD vs. The Competition

Export

Metric	ACADIA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.72B	$3.30B	$6.65B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	9.93	18.68	24.74	23.76
Price / Sales	3.49	297.55	508.64	105.22
Price / Cash	24.46	118.24	42.36	56.09
Price / Book	3.01	8.06	10.47	6.72
Net Income	$391M	$23.83M	$3.56B	$337.35M
7 Day Performance	1.91%	-2.51%	-0.96%	-1.21%
1 Month Performance	-2.50%	2.22%	1.25%	1.41%
1 Year Performance	-1.62%	36.40%	20.49%	23.64%

ACADIA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACAD ACADIA Pharmaceuticals	4.2286 of 5 stars	$21.84 +0.6%	$31.63 +44.8%	-2.1%	$3.72B	$1.07B	9.93	510	Positive News
BBIO BridgeBio Pharma	3.5629 of 5 stars	$67.37 -0.4%	$89.59 +33.0%	+73.4%	$13.24B	$502.08M	N/A	400	Insider Trade
ASND Ascendis Pharma A/S	4.6935 of 5 stars	$205.81 -2.2%	$295.39 +43.5%	+23.1%	$13.13B	$814.57M	23.74	1,189	Positive News Analyst Forecast High Trading Volume
AXSM Axsome Therapeutics	1.839 of 5 stars	$235.14 +1.2%	$251.26 +6.9%	+123.6%	$11.96B	$638.50M	N/A	380	Insider Trade
ELAN Elanco Animal Health	3.2003 of 5 stars	$23.67 +0.2%	$28.20 +19.1%	+75.6%	$11.80B	$4.72B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACAD) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. BBIO, ASND, AXSM, ELAN, and SMMT

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does ACADIA Pharmaceuticals compare to Elanco Animal Health?

Summary

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Competitors

ACAD vs. BBIO, ASND, AXSM, ELAN, and SMMT

How does ACADIA Pharmaceuticals compare to BridgeBio Pharma?

Which has more volatility and risk, BBIO or ACAD?

Does the media prefer BBIO or ACAD?

Is BBIO or ACAD more profitable?

Do insiders and institutionals believe in BBIO or ACAD?

Which has preferable earnings & valuation, BBIO or ACAD?

Do analysts rate BBIO or ACAD?

Summary

How does ACADIA Pharmaceuticals compare to Ascendis Pharma A/S?

Does the media favor ACAD or ASND?

Do analysts recommend ACAD or ASND?

Which has higher valuation & earnings, ACAD or ASND?

Do insiders and institutionals have more ownership in ACAD or ASND?

Is ACAD or ASND more profitable?

Which has more volatility and risk, ACAD or ASND?

Summary

How does ACADIA Pharmaceuticals compare to Axsome Therapeutics?

Do institutionals & insiders have more ownership in AXSM or ACAD?

Which has more volatility and risk, AXSM or ACAD?

Does the media prefer AXSM or ACAD?

Do analysts recommend AXSM or ACAD?

Which has stronger earnings & valuation, AXSM or ACAD?

Is AXSM or ACAD more profitable?

Summary

How does ACADIA Pharmaceuticals compare to Elanco Animal Health?

Do analysts rate ACAD or ELAN?

Do insiders & institutionals hold more shares of ACAD or ELAN?

Is ACAD or ELAN more profitable?

Which has more risk and volatility, ACAD or ELAN?

Does the media prefer ACAD or ELAN?

Which has preferable earnings & valuation, ACAD or ELAN?

Summary

How does ACADIA Pharmaceuticals compare to Summit Therapeutics?

Does the media refer more to SMMT or ACAD?

Which has higher earnings & valuation, SMMT or ACAD?

Do analysts rate SMMT or ACAD?

Which has more risk & volatility, SMMT or ACAD?

Do insiders and institutionals have more ownership in SMMT or ACAD?

Is SMMT or ACAD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACAD vs. The Competition

ACADIA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools